Is Operation TrialBlazer America’s response to China biotech acceleration?

“The world is a better, safer, healthier, and more prosperous place when the US and its allies continue to lead in biotechnology” – John F. Crowley, President & CEO, BIO

At the 2026 BIO International Convention, discussions about scientific innovation were accompanied by a broader concern: whether the United States (US) can retain its position at the centre of global biotechnology ecosystem as China rapidly expands its capabilities¹. The concern is no longer confined in industry commentary but also presented as an official warning by the National Security Commission on Emerging Biotechnology that China’s progress is being supported by sustained public investment, industrial coordination, access to large datasets, and an increasingly capable commercial biotechnology sector².

Against this backdrop, the Department of Health and Human Services (HHS) launched Operation TrialBlazer on 22 June 2026³. Officially, TrialBlazer is a department-wide initiative to strengthen US leadership in clinical research, accelerate the development of new treatments, and make the country a more attractive location for clinical trials³. But viewed in context, could this represent a wider attempt to address the institutional frictions that may be weakening America’s competitiveness in biotech?

What is Operation TrialBlazer?

Operation TrialBlazer is an HHS-wide framework involving the Food and Drug Administration (FDA), National Institutes of Health (NIH), National Cancer Institute (NCI), National Canter for Advancing Translational Sciences (NCATS), the Office of the National Coordination for Health Information Technology (ONC), the Advanced Research Projects Agency for Health (ARPA-H) and other federal bodies³. Its individual measures cover different parts of the clinical research system, but they share the common objective of reducing avoidable delays in research and clinical development without compromising scientific rigour or participant protection.

From the FDA side, some of the expected reforms include:

1.     A faster route to first-in-human trials

• The FDA is seeking feedback on an Expedited Investigational New Drug (IND) pilot program intended to shorten the period between identifying a drug candidate and beginning a Phase I trial⁴
• Under the proposed model, sponsors would collaborate with qualified research institutions (e.g., academic medical centres, contract research organisations) and use a rolling IND submission process. This would create a more iterative pre-IND pathway in which regulatory questions could be identified earlier, potentially improving submission quality and reducing the risk of clinical holds⁴
• The FDA has also clarified the chemistry, manufacturing and controls (CMC) information expected for first-in-human studies. According to the agency, companies have sometimes submitted more information than necessary at this stage, creating additional work without a proportionate benefit for early clinical decision-making. The FDA estimates that focusing on phase-appropriate requirements could save 6-12 months of development time⁴

2.     Reconsidering the default expectation of 2 pivotal trials

• The FDA has revised its draft guidance on demonstrating substantial evidence of effectiveness. The guidance clarifies that, in appropriate circumstances, one rigorous, adequate and well-controlled pivotal investigation, supported by confirmatory evidence, may be sufficient to establish substantial evidence of effectiveness for approval⁴

3.     Greater use of real-world evidence (RWE)

• The FDA defines RWE as clinical evidence regarding the use, potential benefits or risks of a medical product derived from the analysis or real-world data⁵
• The agency’s 2026 draft guidance on Bayesian methodologies also discusses incorporating previous clinical studies, RWE and external, non-concurrent controls into trial analyses⁶. Bayesian methods may help sponsors identify failure or success earlier, inform subsequent trial design and support inference in rare or paediatric populations, where conventional trials might be difficult to conduct⁶

4.     AI-enabled and “real-time” clinical trials

• Traditionally, trial data pass from research sites to sponsors, undergo cleaning and analysis, and are subsequently submitted to the FDA, creating lags between events occurring in a study and the regulator reviewing the resulting safety or efficiency
• Consequently, the FDA announced 2 proof-of-concept studies in which selected endpoints and data signals would be reported to the agency in real time. The agency also requested input on a broader pilot program in real-time clinical trials⁷

NIH, ONC and the infrastructure around TrialBlazer

• Recognising that the FDA reform cannot solve the problem alone, the NIH is expected to strengthen support for informative and appropriately powered clinical trials while advancing responsible applications of AI, real-world data, human cell-based models and practical trial tools³
• NCATS is also building on experience gained through the development of a fully personalised CRISPR-based therapy, with the aim of accelerating future treatments for patients with rare diseases³
• The NCI is working with cancer centres and other stakeholders to streamline trial activation and improve enrolment³
• Meanwhile, ONC is exploring how electronic health records could connect eligible patients with relevant clinical trials as part of routine care³

The economic logic behind regulatory speed

HHS has explicitly linked the initiative to a concern that a growing share of early-stage clinical research is moving overseas. Its stated objective is to make the US the preferred location for clinical research once again³. If the US can reduce unnecessary delay while maintaining credible evidentiary standards, it may reclaim its attractiveness for domestic and international investment in this area of clinical development.

Regulatory reform or industrial policy?

Scientific capability alone does not determine where a medicine is developed. The US government assessments describe China as combining rapid scientific development with coordinated government support, expanding clinical infrastructure, large patient populations and comparatively lower operating costs². China has also undertaken reforms intended to improve the speed and international alignment of its clinical development and regulatory systems². The strategic concern is therefore not simply that more research is taking place in China, but that it is building a system capable of moving an increasing number of assets through the clinical development funnel at speeds and costs that may be more attractive to global pharmaceutical companies. However, US lawmakers have questioned reliance on China-generated early-stage clinical data to support IND applications, citing limited FDA inspection capacity, difficulties verifying informed consent and human-rights safeguards and potential state inference⁸. Operation TrialBlazer is not officially presented as an anti-China initiative. Its immediate objectives concern patients, research participation and clinical development efficiency. Nevertheless, the language surrounding the initiative is unmistakably strategic. HHS describes TrialBlazer as an effort to “restore American leadership“ in clinical research, strengthen domestic research capacity and bring clinical research and investment back to the US³.

Article by Demetria-Ilinca Panait

Sources:

1. Biotechnology Innovation Organisation (BIO) (2026). BIO returns to San Diego to Celebrate Five Decades of Biotechnology. Available at: https://www.bio.org/press-release/bio-international-convention-returns-san-diego-celebrate-five-decades-biotechnology [Accessed 22 July 2026]
2. National Security Commission on Emerging Biotechnology (2025). The Future of U.S.-China Biotechnology Competition. Available at: https://www.biotech.senate.gov/wp-content/uploads/2025/12/NSCEB-Future-of-U.S.-China-Biotech-Competition-Dec-2025.pdf [Accessed 22 July 2026]
3. US Department of Health and Human Services (2026). HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials. Available at: https://www.hhs.gov/press-room/hhs-launches-clinical-trials-reform-initiative.html [Accessed 22 July 2026]
4. FDA (2026). FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development. Available at: https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development [Accessed 22 July 2026]
5. FDA (2026). Real-World Evidence. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence [Accessed 23 July 2026]
6. FDA (2026). FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials. Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials [Accessed 23 July 2026]
7. FDA (2026). FDA Announces Major Steps to Implement Real-Time Clinical Trials. Available at: https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials [Accessed 23 July 2026]
8. US Congress (2026). AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS BILL, 2027. Available at: https://www.congress.gov/119/crpt/hrpt632/CRPT-119hrpt632.pdf [Accessed 24 July 2026]

‍